InsidersTradesSigma
申报总数
公司
▲ 买入（3 笔）
▼ 卖出（0 笔）
内部人交易记录
其他已披露买入
3
已披露卖出
0
T+90 胜率
50%
T+90 平均收益
+32.9%
基于 2 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the full record of transactions filed by Roivant Sciences Ltd.. Director active across 2 companies, notably Immunovant, Inc.. Cumulatively, 6 disclosures have been logged. Split: 3 buys · 0 sell. Total volume traded: €629.6m. History available since 6 October 2022. The latest transaction was disclosed on 12 December 2025 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Roivant Sciences Ltd.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报6 总计
16,666,666 股@ US$21.0037.7% 占其流量Common Stock, $0.0001 par value per shareSEC:0001140361-25-045409:0
标准退出：2026年3月12日 (T+90)
16,845,010 股@ US$20.0066.6% 占其流量Common Stock, $0.0001 par value per shareSEC:0001140361-25-001188:0
标准退出：2025年4月13日 (T+90)
4,473,684 股@ US$38.0032.9% 占其流量Common Stock, $0.0001 par value per shareSEC:0001140361-23-046976:0
416,667 股@ US$6.000.5% 占其流量Common Stock, $0.0001 par value per shareSEC:0001140361-22-036652:0
标准退出：2023年1月4日 (T+90)
22,833,922 股Common shares, without par valueSEC:0000950103-21-016172:0
17,021,276 股Common Stock, $0.0001 par value per shareSEC:0001104659-21-099083:0
6 条申报中的 6 条
About Roivant Sciences Ltd.
Roivant Sciences Ltd. has 7 filings in total. Among the recent filings held here, they span the period from 2021-08-02 to 2025-01-15, with EUR 331415659 of purchases and EUR 0 of sales. The filings concern Immunovant, Inc., where the company is listed as Director, and Arbutus Biopharma Corp.
